Aktienanalyse zu Prestige Consumer Healthcare Inc (PBH)PBHPrestige Consumer Healthcare Inc

Prestige Consumer Healthcare Inc. develops, manufactures, markets, sells and distributes over-the-counter (OTC) health and personal care products to mass merchandisers, drug/drug wholesale, food, dollar, convenience and club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Breathe Right nasal strips, Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart treatments, Little Remedies pediatric over-the-counter products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment, Debrox earwax remover, and others. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Prestige Consumer Healthcare Inc is a good buy right now due to its current price of $52.47, which is below the analyst price target of $72 from Canaccord, indicating significant upside potential. Additionally, the company reported a 6.5% increase in sales for Q1 2027, reaching approximately $266 million, and has a forward P/E ratio of 11.51, suggesting it is undervalued compared to its earnings potential. However, a key risk is its net leverage, which is currently around 4.0x EBITDA, indicating financial strain from its recent acquisitions.

7 analysts cover PBH: 5 rate it Buy, 2 Hold and 0 Sell. The average price target is 76.00.